ArticleFrontiers in pharmacology2018

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.

Gianluca Trifirò et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.